<DOC>
	<DOCNO>NCT00534183</DOCNO>
	<brief_summary>`` No clinical difference find three antipsychotic study - olanzapine , risperidone haloperidol - patient ' metabolic profile weight. ``</brief_summary>
	<brief_title>Metabolic Profile Anthropometric Changes Schizophrenia</brief_title>
	<detailed_description>aim study effect antipsychotic , olanzapine , risperidone haloperidol development metabolic syndrome drug na√Øve population suffer first episode schizophrenia compare match healthy control group . We also aim examine prevalence metabolic syndrome define two widely accept definition , ATP IIIA IDF .</detailed_description>
	<mesh_term>Schizophrenia</mesh_term>
	<mesh_term>Metabolic Syndrome X</mesh_term>
	<mesh_term>Haloperidol</mesh_term>
	<mesh_term>Olanzapine</mesh_term>
	<mesh_term>Haloperidol decanoate</mesh_term>
	<mesh_term>Risperidone</mesh_term>
	<criteria>Age 1840 year Diagnosis schizophrenia Drug naive admission Other psychiatric comorbidity History severe physical illness Alcohol substance abuse dependence History preexisting diabetes hypertension Family history hypertension diabetes</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>40 Years</maximum_age>
	<verification_date>September 2007</verification_date>
	<keyword>Metabolic syndrome</keyword>
	<keyword>Obesity</keyword>
	<keyword>Diabetes</keyword>
</DOC>